UBS Group’s Maravai LifeSciences MRVI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.79M | Buy |
3,232,284
+2,676,831
| +482% | +$6.45M | ﹤0.01% | 2655 |
|
|
2025
Q1 | $1.23M | Sell |
555,453
-1,395,690
| -72% | -$3.08M | ﹤0.01% | 4036 |
|
|
2024
Q4 | $10.6M | Buy |
1,951,143
+1,717,771
| +736% | +$9.36M | ﹤0.01% | 2276 |
|
|
2024
Q3 | $1.94M | Buy |
233,372
+66,349
| +40% | +$551K | ﹤0.01% | 3053 |
|
|
2024
Q2 | $1.2M | Buy |
167,023
+76,955
| +85% | +$551K | ﹤0.01% | 3243 |
|
|
2024
Q1 | $781K | Sell |
90,068
-63,425
| -41% | -$550K | ﹤0.01% | 3735 |
|
|
2023
Q4 | $1.01M | Buy |
153,493
+96,217
| +168% | +$630K | ﹤0.01% | 3438 |
|
|
2023
Q3 | $573K | Sell |
57,276
-84,192
| -60% | -$842K | ﹤0.01% | 3515 |
|
|
2023
Q2 | $1.76M | Buy |
141,468
+27,624
| +24% | +$343K | ﹤0.01% | 2804 |
|
|
2023
Q1 | $1.59M | Buy |
113,844
+23,150
| +26% | +$324K | ﹤0.01% | 2795 |
|
|
2022
Q4 | $1.3M | Buy |
90,694
+6,736
| +8% | +$96.4K | ﹤0.01% | 2929 |
|
|
2022
Q3 | $2.14M | Sell |
83,958
-9,171
| -10% | -$234K | ﹤0.01% | 2307 |
|
|
2022
Q2 | $2.65M | Sell |
93,129
-8,201
| -8% | -$233K | ﹤0.01% | 2200 |
|
|
2022
Q1 | $3.57M | Sell |
101,330
-20,302
| -17% | -$716K | ﹤0.01% | 2206 |
|
|
2021
Q4 | $5.1M | Sell |
121,632
-17,554
| -13% | -$736K | ﹤0.01% | 2073 |
|
|
2021
Q3 | $6.83M | Sell |
139,186
-11,481
| -8% | -$563K | ﹤0.01% | 1744 |
|
|
2021
Q2 | $6.29M | Buy |
150,667
+80,369
| +114% | +$3.35M | ﹤0.01% | 1835 |
|
|
2021
Q1 | $2.51M | Buy |
70,298
+34,423
| +96% | +$1.23M | ﹤0.01% | 2568 |
|
|
2020
Q4 | $1.01M | Buy |
+35,875
| New | +$1.01M | ﹤0.01% | 3160 |
|